ArticleHaematologica2025
Cytogenetic abnormalities in polycythemia vera: phenotypic correlates and prognostic relevance in 669 informative cases.
Article in Haematologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Molecular Abnormalities and Associated Clinical Features in Polycythemia Vera.Medical sciences (Basel, Switzerland) · 2026Review
- Current Advances in the Diagnosis and Treatment of Major Myeloproliferative Neoplasms.Cancers · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The main objective of the current study was to provide a detailed account of the prognostic relevance of abnormal karyotype and associated specific cytogenetic abnormalities in polycythemia vera (PV). Six hundred and sixty-nine PV patients were informative, of whom 436 (65%) were evaluated within 1 year of diagnosis. Karyotype abnormalities were found in 67 (15%) patients, including isolated abnormalities of loss of Y chromosome (-Y; N=15; 3%), +9 (N=11; 3%), del(20q) (N=10; 2%), and +8 (N=4; 1%). Abnormal karyotype correlated with older age (P<0.01), lower platelet count (P<0.01), and grade ≥2 reticulin fibrosis (P<0.01). Specifically, del(20q) correlated with older age and grade ≥2 reticulin fibrosis, while +9 correlated with a higher incidence of a history of venous thrombosis. SRSF2 and IDH2 mutations clustered with normal karyotype. At a median follow-up of 7.4 years, 163 (37%) deaths, 50 (11%) cases of fibrotic transformation (post-PV MF) and 14 (3%) cases of leukemic transformation (LT) were documented. In univariate analysis, abnormal karyotype was associated with inferior overall survival (median 10.5 vs. 16.3 years; P<0.01); the statistical significance of this association was sustained in multivariable analysis (hazard ratio=2.0; P=0.02), along with associations with age ≥60 years (P<0.01), leukocytosis ≥15×109/L (P<0.01) and SRSF2 mutation (P<0.01). Abnormal karyotype was also associated with post-PV MF (21% vs. 10%; P<0.01) and LT (7% vs. 2%; P<0.01); the statistical significance of this association was sustained in multivariable analysis for post-PV MF (hazard ratio=3.7; P<0.01), but not for LT (P=0.47). In regard to specific abnormalities, del(20q) was associated with progression to post-PV MF and ≥2 abnormalities with LT. The current study describes the spectrum of cytogenetic abnormalities in PV and their associated phenotypic and prognostic correlates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.